Good afternoon :)
$
₹
BioAge Labs, Inc

BioAge Labs, Inc

BIOA

NASDAQ
Asset Logo

BioAge Labs, Inc

BIOA

NASDAQ
$5.546.78% (-0.40)
$
₹
$5.546.78% (-0.40)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Micro Cap

With a market cap of $273.5M the stock is ranked 3913

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.71
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.46
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 10 analysts reports

Buy
7 analysts
Hold
3 analysts
Sell
0 analyst

Price Upside

+447.15%

Earnings Growth

-8.32%

Rev. Growth

-16.32%

See Detailed Forecast

Company Profile

Company Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.78
45.78
1Y Return
47.62%
47.62%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.39
40.39
1Y Return
47.33%
47.33%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.14
149.14
1Y Return
74.12%
74.12%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.39
30.39
1Y Return
29.02%
29.02%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.00
26.00
1Y Return
14.37%
14.37%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$5.95Baseline
Analyst Target - 1 year
Target$32.56+447.15%

All values in $

20232024202520262027$12.86$20.51$28.16Target+447.15%
2026
Current$5.95Baseline
Analyst Target - 1 year
Target$32.56+447.15%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$8.99Baseline
Forecast for Dec 2026
High$10.40+15.69%
Average$7.52-16.32%
Low$5-44.41%

All values in $ Million

20172022202320242025202614.940008.99Low-44.41%Average-16.32%High+15.69%
2025
Current$8.99Baseline
Forecast for Dec 2026
High$10.40+15.69%
Average$7.52-16.32%
Low$5-44.41%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.24Baseline
Forecast for Dec 2026
High$-2.14+4.46%
Average$-2.43-8.32%
Low$-2.77-23.5%

All values in $

20222023202420252026N/AN/A-8.3-2.24Low-23.5%Average-8.32%High+4.46%
2025
Current$-2.24Baseline
Forecast for Dec 2026
High$-2.14+4.46%
Average$-2.43-8.32%
Low$-2.77-23.5%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2
-20.1
3
-25.9
2.7
-22.2
2.4
-26
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00001.452.412.053.072.772.45
Net Income-12.99-13.58-23.40-21.12-12.92-21.56-20.17-25.94-22.25-26.09
Net Profit Margin-----890.97%-893.98%-982.03%-842.85%-802.77%-1064.74%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
BioAge Labs, Inc -0.71-
Eli Lilly and Company45.7831.351.35
Johnson & Johnson40.397.983.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BIOA with any stock or ETF
Compare BIOA with any stock or ETF
Comparing from
BIOA
LLY
JNJ
Loading...

Frequently asked questions

  1. BioAge Labs, Inc (BIOA) share price today is $5.54 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $6.03 and a day low of $5.44.

  2. BioAge Labs, Inc stock trades on NASDAQ under the ticker symbol BIOA.

  3. BioAge Labs, Inc's market capitalization is $273.54M as of November 6, 2026 at 2:29 AM IST.

  4. BioAge Labs, Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. BioAge Labs, Inc's price-to-book (P/B) ratio is 0.71 as of November 5, 2026.

  6. Yes, You can buy BioAge Labs, Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy BioAge Labs, Inc shares in three steps: 1. Search BioAge Labs, Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since BioAge Labs, Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in BioAge Labs, Inc (BIOA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.8031 shares at the current price of $5.54.

Loading...